A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer
Phase of Trial: Phase I/II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Capmatinib (Primary) ; Nazartinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 19 Jul 2017 Planned End Date changed from 3 Jun 2019 to 23 Dec 2018.
- 19 Jul 2017 Planned primary completion date changed from 3 Jun 2019 to 29 Jun 2018.
- 23 Feb 2017 Planned number of patients changed from 118 to 130.